{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:00:38Z","timestamp":1794808838873,"version":"4.9.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJPF2017"],"award-info":[{"award-number":["JPMJPF2017"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP256f0137008"],"award-info":[{"award-number":["JP256f0137008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eururo.2025.12.019","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T20:08:19Z","timestamp":1768680499000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0332-4791","authenticated-orcid":false,"given":"Yoshiyuki","family":"Nagumo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Sekino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan J.","family":"Mathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ushijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideomi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nihei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Naiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuo","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yoshio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadamasa","family":"Yoshitake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.12.019_b0005","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.12.019_b0010","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.12.019_b0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.12.019_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2021.100724","article-title":"Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART) \u2013 a study protocol for an open-label, phase II, multicenter study","volume":"21","author":"Sekino","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.eururo.2025.12.019_b0025","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijrobp.2023.05.013","article-title":"Efficacy and safety of bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer: interim analysis from a multicenter, open-label, prospective phase 2 trial","volume":"117","author":"Kimura","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.12.019_b0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0936-6555(05)80838-6","article-title":"Bladder cancer: long-term follow-up results of patients treated with radical radiation","volume":"3","author":"Gospodarowicz","year":"1991","journal-title":"Clin Oncol"},{"key":"10.1016\/j.eururo.2025.12.019_b0035","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1002\/1097-0142(19931115)72:10<3036::AID-CNCR2820721028>3.0.CO;2-B","article-title":"Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients","volume":"72","author":"Foss\u00e5","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.12.019_b0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0360-3016(94)90004-3","article-title":"Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors","volume":"30","author":"Pollack","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.12.019_b0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/clon.2002.0055","article-title":"Radical radiotherapy and salvage cystectomy as the primary management of transitional cell carcinoma of the bladder. Results following the introduction of a CT planning technique","volume":"14","author":"Borgaonkar","year":"2002","journal-title":"Clin Oncol"},{"key":"10.1016\/j.eururo.2025.12.019_b0050","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euo.2023.09.011","article-title":"Pembrolizumab with chemoradiation as treatment for muscle-invasive bladder cancer: analysis of safety and efficacy of the PCR-MIB phase 2 clinical trial (ANZUP 1502)","volume":"7","author":"Weickhardt","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2025.12.019_b0055","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1200\/JCO.2023.41.16_suppl.4509","article-title":"Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): a multicenter phase 2 trial","volume":"41","author":"Economides","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.12.019_b0060","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1078-0432.CCR-24-2636","article-title":"Bladder preservation with durvalumab plus tremelimumab and concurrent radiotherapy in patients with localized muscle-invasive bladder cancer (IMMUNOPRESERVE): a phase II Spanish Oncology GenitoUrinary Group trial","volume":"31","author":"Garcia-Del-Muro","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.12.019_b0065","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2018.04.070","article-title":"Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer","volume":"101","author":"Tree","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2025.12.019_b0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.18.00145","article-title":"Trial Reporting in Immuno-Oncology (TRIO): an American Society of Clinical Oncology-Society for Immunotherapy of Cancer statement","volume":"37","author":"Tsimberidou","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825048729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825048729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:50:04Z","timestamp":1773960604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825048729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":14,"alternative-id":["S0302283825048729"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.12.019","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}